

Abnormal Transmethylation/transsulfuration Metabolism and DNA Hypomethylation Among Parents of Children with Autism

S. Jill James · Stepan Melnyk · Stefanie Jernigan · Amanda Hubanks · Shannon Rose · David W. Gaylor

© Springer Science+Business Media, LLC 2008

Abstract An integrated metabolic profile reflects the combined influence of genetic, epigenetic, and environmental factors that affect the candidate pathway of interest. Recent evidence suggests that some autistic children may have reduced detoxification capacity and may be under chronic oxidative stress. Based on reports of abnormal methionine and glutathione metabolism in autistic children, it was of interest to examine the same metabolic profile in the parents. The results indicated that parents share similar metabolic deficits in methylation capacity and glutathione-dependent antioxidant/detoxification capacity observed in many autistic children. Studies are underway to determine whether the abnormal profile in parents reflects linked genetic polymorphisms in these pathways or whether it simply reflects the chronic stress of coping with an autistic child.

Keywords Autism · Homocysteine · Glutathione · DNA methylation · Parents

Introduction

Autism is a behaviorally-defined neurodevelopmental disorder that is usually diagnosed in early childhood and is characterized by impairment in reciprocal communication and speech, social withdrawal, and repetitive hyper-focused behaviors. The 10-fold increase in autism diagnosis in the last decade now affecting ~1 in 150 children in the US has justifiably raised great public health concern (CDC 2005). Although both genetic and environmental factors are thought to be involved in the genesis of autism, none as yet have been reproducibly identified. Metabolic dysfunction has not been extensively studied in autistic children despite the fact that chronic biochemical imbalance is often a primary factor in the development of complex neurologic disease (Pennington et al. 2007; Kilbourne et al. 2007; Giordano et al. 2007).

In a recent study, we measured baseline levels of methionine transmethylation and transsulfuration metabolites in plasma from 80 autistic children (James et al. 2006). Briefly, we showed that the mean ratio of plasma S-adenosylmethionine (SAM) to S-adenosylhomocysteine (SAM/SAH ratio), an index of cellular methylation capacity, was 50% of that in 75 age-matched control children. We also demonstrated a decrease in glutathione (GSH), the major intracellular antioxidant and an increase in oxidized glutathione (GSSG), resulting in a ~3-fold reduction in the ratio of reduced (active) GSH to oxidized (inactive) glutathione (GSH/GSSG). Glutathione precursors were also lower suggesting inadequate GSH synthesis. These new findings are of concern because they indicate a significant decrease in methylation capacity (\downarrow SAM/SAH) and redox potential (\downarrow GSH/GSSG) and an increase in oxidative stress (\uparrow GSSG). Evidence from several other laboratories similarly indicates that biomarkers of

S. Jill James · S. Melnyk · S. Jernigan · A. Hubanks · S. Rose
Department of Pediatrics, University of Arkansas for Medical
Sciences, Little Rock, AR 72202, USA

S. Jill James (✉)
Arkansas Children's Hospital Research Institute, 1120 Marshall
St. Slot 512-40B, Little Rock, AR 72202, USA
e-mail: jamesjill@uams.edu

D. W. Gaylor
Department of Biostatistics, University of Arkansas for Medical
Sciences, Little Rock, AR 72202, USA

oxidative stress may be increased in some autistic children. (Ming et al. 2005; Chauhan et al. 2004; Sogut et al. 2003; Zoroglu et al. 2004; Yao et al. 2006b).

Figure 1 is an overview of the three interdependent pathways involved in folate-dependent methionine transmethylation and transsulfuration. Pathway 1 is the folate cycle, Pathway 2 is the methionine cycle, and Pathway 3 is the transsulfuration pathway leading to glutathione synthesis. The functional importance of these pathways is underscored by their essentiality for error-free DNA synthesis (Pathway 1); for cellular methylation reactions including DNA, RNA, protein, and phospholipid methylation (Pathway 2); and for the maintenance of cellular redox and detoxification capacity (Pathway 3). The GSH/GSSG ratio reflects the redox potential of the intracellular environment which is critical for maintenance of normal redox signaling, antioxidant and detoxification capacity (Wu et al. 2004; Filomeni et al. 2002; Pastore et al. 2003). Glutathione is present in millimolar concentrations inside the cell and is the major determinant of intracellular redox homeostasis and cell detoxification/antioxidant capacity. Cell functions affected by




Fig. 1 A diagram of tetrahydrofolate (THF)-dependent methionine transmethylation and glutathione synthesis. The methionine cycle (transmethylation) involves the regeneration of methionine from homocysteine via the B12-dependent transfer of a methyl group from 5-methyl-tetrahydrofolate ($5\text{-CH}_3\text{THF}$) via the methionine synthase (MS) reaction. Methionine is then activated to S-adenosylmethionine (SAM), the methyl donor for multiple cellular methyltransferase (MTase) reactions and the methylation of essential molecules such as DNA, RNA, proteins, phospholipids, creatine, and neurotransmitters. The transfer of the methyl group from SAM results in the demethylated product S-adenosylhomocysteine (SAH). The reversible hydrolysis of SAH to homocysteine and adenosine by the SAH hydrolase (SAHH) reaction completes the methionine cycle. Homocysteine can then be either remethylated to methionine or irreversibly removed from the methionine cycle by cystathionine beta synthase (CBS). This is a one-way reaction that permanently removes homocysteine from the methionine cycle and initiates the transsulfuration pathway for the synthesis of cysteine and glutathione. Glutathione is shown in its active reduced form (GSH) and inactive oxidized disulfide form (GSSG)

glutathione deficit include cell proliferation (e.g., immune function, DNA synthesis and repair), essential methylation (e.g., DNA, RNA, protein, phospholipid, neurotransmitters, creatine) and redox homeostasis (e.g., cell signaling, detoxification, stress response, cell cycle progression, and apoptosis).

DNA methylation is a post-translational modification of DNA that orchestrates a wide variety of functions including differentiation, tissue-specific gene expression, chromatin structure, imprinted gene expression, silencing of parasitic DNA, and X-chromosome inactivation (Razin 1998; Reik and Dean 2001; Robertson and Jones 2000; Hermann et al. 2004). Folate-dependent transmethylation metabolism is integrally involved in establishing and maintaining patterns of DNA methylation (Friso and Choi 2002; Niculescu and Zeisel 2002). DNA hypomethylation is an “epigenetic” modification that is associated with nutritional and genetic deficiencies in methionine metabolism (Jacob et al. 1998; Yi et al. 2000; Fuso et al. 2005; Friso et al. 2002) aging (Friso and Choi 2002), cancer (Dreosti 1998), and toxic environmental exposures (Feil 2006a; Abdolmaleky et al. 2004). Epigenetic change refers to heritable alteration in gene expression without a change in DNA sequence. The ability of gene expression to adapt and respond to developmental cues and environmental exposures is primarily due to post-translational modifications of DNA methylation and histone methylation/acetylation that alter transcription factor accessibility (Abdolmaleky et al. 2004; Feil 2006b).

The possibility that autism may involve an epigenetic component is supported by reports indicating that only 60–90% of monozygotic twins are concordant for autism (Kates et al. 2004). The fact that the concordance is not 100% strongly suggests that epigenetic DNA alterations and/or gene-environment interactions contribute to the development of autism (Beaudet 2002; Badcock and Crespi 2006). Moreover, the frequency of autism is increased in children with genetic diseases that alter DNA methylation density or function including Fragile X disease, Angelman Syndrome, and Rett Syndrome (Schanen 2006; Lopez-Rangel and Lewis 2006; Samaco et al. 2005). Impaired methylation and glutathione depletion have been documented in several neuropsychiatric disorders including schizophrenia (Regland et al. 1994; Yao et al. 2006b), bipolar disorder (Kuratomi et al. 2007; Frey et al. 2007), and autism (James et al. 2004; James et al. 2006). Based on these considerations and the abnormal transmethylation and transsulfuration metabolites observed in children with autism, it was of considerable interest to examine these pathways in the parents of autistic children as well as their global DNA methylation status.

Methods

Study Participants

Case parents were mothers and fathers of children who had been diagnosed with Autistic Disorder based on *Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition* (DSM-IV) and the Childhood Autistic Rating Scales (CARS). A total of 86 parents participated in the study consisting of 46 mothers and 40 fathers. Of the 86 parents, 72 were mother-father pairs (36 pairs), and ranged in age from 21 to 45 years (mean age \pm SD: 30 ± 5). The ethnicity distribution among case parents was 87% White, 9% Asian, and 4% African American. Control parents for the metabolic study consisted of 200 mothers with a mean age of 28 (range 17–43 years) who were control participants in an ongoing case-control study of maternal risk factors for congenital heart defects (Hobbs et al. 2005a). The ethnicity among the control parents was 75% White, 7% Hispanic, 16% African American, and 2% Asian. All case and control parents were Arkansas residents. Although over-the-counter multivitamin supplement intake was significantly higher among control compared to case mothers (51% vs. 20%), metabolite levels were not significantly altered by vitamin intake within either group ($p > 0.05$ for all metabolites). The protocol was approved by the Institutional Review Board at the University of Arkansas for Medical Sciences and all participants signed informed consent.

Sample Treatment and HPLC Methodology

Fasting blood samples were collected before 9:00 am into EDTA-Vacutainer tubes and immediately chilled on ice before centrifuging at $4,000 \times g$ for 10 min at 4°C . Aliquots of plasma were transferred into cryostat tubes and stored at -80°C for approximately 2–4 weeks until extraction and HPLC quantification. For the determination of total homocysteine (tHcy), methionine, cysteine, and total glutathione, 50 μl freshly prepared 1.43 M sodium borohydride solution containing 1.5 μM EDTA, 66 mM NaOH and 10 μl isoamyl alcohol were added to 200 μl plasma to reduce all sulfhydryl bonds and the samples were incubated at 40°C in a shaker for 30 min. To precipitate proteins, 250 μl ice cold 10% metaphosphoric acid was added, mixed well, and the sample was incubated for an additional 10 min on ice. After centrifugation at $18,000 \times g$ for 15 min at 4°C , the supernatant was filtered through a 0.2 μm nylon membrane filter (PGC Scientific, Frederic, MD) and a 20 μl aliquot was injected into the HPLC system.

For determination of SAM, SAH and free oxidized (GSSG) and free reduced (GSH) glutathione, 100 μl of 10% meta-phosphoric acid was added to 200 μl plasma to

precipitate protein; the solution was mixed well, and incubated on ice for 30 min. After centrifugation for 15 min at $18,000 \times g$ at 4°C , supernatants were passed through a 0.2 μm nylon membrane filter and 20 μl was injected into the HPLC system.

The methodological details for HPLC elution and electrochemical detection have been described previously (Melnyk et al. 2000; Melnyk et al. 1999). The analyses were performed using HPLC with a Shimadzu solvent delivery system (ESA model 580) and a reverse phase C_{18} column (3 μm ; $4.6 \times 150 \text{ mm}$, Shisheido Co., Tokyo, Japan) obtained from Phenomenex (Torrance, CA). The plasma extract was directly injected onto the column using Beckman Autosampler (model 507E). All plasma metabolites were quantified using a model 5200A Coulochem II and CoulArray electrochemical detection systems (ESA, Inc., Chelmsford, MA) equipped with a dual analytical cell (model 5010), a 4 channel analytical cell (model 6210) and a guard cell (model 5020). The concentrations of plasma metabolites were calculated from peak areas and standard calibration curves using HPLC software. Although it was not technically feasible to run all case and control samples simultaneously, the -80°C storage interval was consistently between 2 and 4 weeks to minimize potential metabolite interconversion.

HPLC Determination of 5-methylcystosine and Total Cystosine in DNA

Genomic DNA was extracted from primary lymphocytes using the Puregene Blood Kit from Gentra Systems, Inc. (Minneapolis, MN). RNase A (Sigma, St. Louis, MO) was added to a final concentration of 0.02 mg/ml and DNA incubated at 37°C for 15 min. The purified DNA was digested into component nucleotides using Nuclease P_1 , snake venom phosphodiesterase, and alkaline phosphatase as previously described (Friso et al. 2002). Briefly, DNA was denatured by heating for 3 min at 100°C and rapidly chilled in an ice water bath. One-tenth volume of 0.1 M ammonium acetate, pH 5.3, was added to 2 units of nuclease P_1 (Sigma, St. Louis, MO) for every 0.5 A_{260} unit of DNA and the mixture incubated at 45°C for 2 h. Subsequently, 1/10 volume of 1 M ammonium bicarbonate and 0.002 units of venom phosphodiesterase I (Sigma, St. Louis, MO) were added and the mixture incubated for 2 h at 37°C . To the mixture, 0.5 units of alkaline phosphatase (Sigma, St. Louis, MO) was then added and the incubation continued for an additional hour. The digested nucleotides were stored at -20°C until HPLC analysis.

Statistical Analysis

Case-control differences were calculated using the Student t test with statistical significance set at $p \leq 0.05$. Linear

regression analysis was used to calculate the correlation coefficients between selected metabolites and level of 5-methylcytosine using software within Microsoft Excel. Odds ratios (OR) for case compared to control mothers were calculated as an estimate of association between metabolite levels and the relative risk of being a mother of an autistic child. Throughout, a two-tailed *p* value of 0.05 was interpreted as a statistically significant difference.

Results

Plasma Transmethylation Metabolite Levels Among Cases and Controls

The data presented in Table 1 indicate that plasma levels of methionine and SAM were not statistically different among case parents and controls. However, the mean levels of homocysteine and SAH were significantly elevated in case mothers compared to control mothers. Statistical evaluation of case fathers was not possible because blood samples from control fathers were not available from this cohort. Elevations in mean homocysteine and/or SAH levels were not statistically different between case mothers and fathers.

Because SAH is a potent product inhibitor of the DNA methyltransferase, the results were further stratified by SAH levels. Previous studies have shown that SAH levels $>30 \mu\text{Mol/l}$ are associated with significant DNA hypomethylation (Yi et al. 2000). As shown in Table 1, among the 200 controls, 14.9% had SAH levels $>30 \mu\text{Mol/l}$ whereas 56.4% of the 86 case parents had SAH levels $>30 \mu\text{Mol/l}$. Both mother and father contributed a blood sample in 72 of the 86 participants (36 pairs). In 39% of the parent pairs (14/36), both parents had SAH levels $>30 \mu\text{Mol/l}$. Whereas mean SAM levels were not different between cases and controls, the ratio of SAM/SAH among the case parents was significantly decreased primarily reflecting the increase in SAH levels. Figure 2a demonstrates the strong and significant negative correlation between SAH levels and the SAM/SAH ratio among case parents ($r = -0.80$; $p < 0.001$).




Fig. 2 (a) A scatterplot showing the correlation between plasma levels of SAH and the ratio of SAM/SAH among the case parents indicating that the SAM/SAH ratio is primarily driven by the concentration of SAH. (b) A scatterplot showing the strong correlation between free and total plasma glutathione levels among case parents. (c) A scatterplot showing the correlation between plasma SAH levels and DNA hypomethylation (% 5-methylcytosine/total cytosine in DNA)

Table 1 Comparison of plasma metabolite concentrations in the transmethylation pathway between case and control parents

Plasma transmethylation metabolites (Mean \pm SD)	Control mothers <i>N</i> = 200	Case mothers <i>N</i> = 46	Case fathers <i>N</i> = 40
Methionine ($\mu\text{Mol/l}$)	26 \pm 4.7	23 \pm 4.1	26 \pm 5.5
SAM (nMol/l)	83 \pm 14	78 \pm 20	85 \pm 16
SAH (nMol/l)	23 \pm 8.1	33 \pm 14 ^a	37 \pm 15
% of subjects with SAH $>30 \mu\text{Mol/l}$	14.9%	54.3% ^a	59%
SAM/SAH ratio	4.0 \pm 1.4	2.8 \pm 1.6 ^a	2.7 \pm 1.4
Homocysteine ($\mu\text{Mol/l}$)	7.42 \pm 1.7	9.8 \pm 3.6 ^a	10.6 \pm 2.5

^a $p < 0.001$ Case versus control mothers

Plasma Transsulfuration Metabolite Levels Among Cases and Controls

Total GSH reflects combined protein-bound and free GSH after reduction of disulfide bonds whereas free GSH reflects GSH remaining after protein precipitation. Relative to control levels, parents of autistic children were found to have significant decreases in both total and free GSH levels and in the GSH/GSSG ratios whereas the levels of the oxidized disulfide GSSG were significantly increased (Table 2). Cysteine levels among the case parents were not significantly different from controls. Fig. 2b shows a strong and significant correlation between plasma total GSH and free GSH among case parents ($r = 0.88$; $p < 0.001$).

DNA Methylation and Metabolite Correlations

The percent 5-methylcytosine/total cytosine in digested DNA from case and control parents is presented in Table 3. Data are presented for combined parents because there is no known gender effect on DNA methylation. DNA from parents with SAH levels $>30 \mu\text{Mol/l}$ was more hypomethylated than parents with normal SAH levels (5.9% vs. 7.0% 5-methylcytosine/cytosine; $p < 0.001$). There was no statistical difference in DNA methylation between parents or controls who had SAH levels $<30 \mu\text{Mol/l}$. The scatterplot in Fig. 2c shows the negative correlation between SAH and % 5-methylcytosine in DNA ($r = -0.43$; $p < 0.01$) consistent with the inhibitory effect of SAH on the DNA methyltransferase. There was no correlation between 5-methylcytosine and SAM or homocysteine (data not shown).

Table 2 Comparison of the plasma metabolite concentrations between case and control parents

Plasma transsulfuration metabolites (Mean \pm SD)	Control mothers <i>N</i> = 200	Case mothers <i>N</i> = 46	Case fathers <i>N</i> = 40
Cysteine ($\mu\text{Mol/l}$)	229 \pm 22	227 \pm 34	243 \pm 356
Total GSH ($\mu\text{Mol/l}$)	7.3 \pm 1.6	5.1 \pm 1.4 ^a	5.7 \pm 1.6
Free GSH ($\mu\text{Mol/l}$)	2.6 \pm 0.7	1.5 \pm 0.4 ^a	1.6 \pm 0.5
GSSG ($\mu\text{Mol/l}$)	0.24 \pm 0.07	0.32 \pm 0.08 ^a	0.30 \pm 0.09
Total GSH/GSSG ratio	31 \pm 10	17 \pm 8.3 ^a	20.2 \pm 7.2
Free GSH/GSSG ratio	10.7 \pm 4.2	5.1 \pm 2.2 ^a	5.6 \pm 2.2 ^a

^a Case versus control mothers; $p < 0.001$

Table 3 Comparison of the percent methylcytosine/total cytosine in DNA stratified by SAH levels

Group	<i>N</i>	%-Methylcytosine/cytosine (Mean \pm SD)
Combined parents	86	6.4 \pm 1.3 ^b
Controls with SAH $<30 \mu\text{Mol/l}$	15	6.6 \pm 0.5 ^b
Parents with SAH $<30 \mu\text{Mol/l}$	38	7.0 \pm 1.5 ^b
Parents with SAH $>30 \mu\text{Mol/l}$	48	5.9 \pm 1.2 ^a

^a $p < 0.001$: SAH >30 versus SAH <30

^b Not statistically different

SAM/SAH and GSH/GSSG and Maternal Odds Ratios

The data in Table 4 present the calculated odds ratios (OR) and 95% confidence intervals (CI) associated with maternal SAH levels and ratios of SAM/SAH and GSH/GSSG independently and combined. An elevation in SAH $>30 \mu\text{mol/l}$ or a SAM/SAH ratio <2.5 increased the likelihood of being a mother with an autistic child by 7.3-fold and 10.7-fold, respectively. In the transsulfuration pathway, mothers whose GSH/GSSG ratio was <20 had a 15.2-fold increase in the likelihood of being a mother of a child with autism. Most remarkably, among mothers who exhibited both SAM/SAH ratio <2.5 and a GSH/GSSG ratio <20 (41% of mothers), the odds ratio was 46. Odds ratios were not calculated for case fathers because metabolic data from control fathers was not available.

Discussion

The results of this study demonstrate for the first time that some parents of children with autism exhibit significant metabolic deficits in methylation capacity (\downarrow SAM/SAH) and in glutathione-mediated antioxidant and detoxification capacity (\downarrow GSH/GSSG). A remarkably similar metabolic imbalance was recently observed in many autistic children (James et al. 2004; James et al. 2006). Preliminary evidence in the autistic children suggests that genetic polymorphisms affecting enzymes in transmethylation and transsulfuration metabolic pathways may contribute, in part, to the metabolic imbalance (James et al. 2006). The observation that both parents and children with autism share a common metabolic phenotype is consistent with an

Table 4 Odds ratios and 95% confidence intervals for the association between maternal plasma biomarkers and the likelihood of being a mother of an autistic child

Stratified group	Control mothers ^a N (%)	Case mothers ^b N (%)	Odds ratio (95% CI)
SAH >30 μMol/l)	28 (14)	25 (54.3)	7.3 (3.6, 14.8)
SAM/SAH <2.5	20 (10)	25 (54.3)	10.7 (5.1, 22.5)
tGSH/GSSG <20	22 (11)	30 (65.2)	15.2 (7.2, 32.1)
SAM/SAH <2.5 and tGSH/GSSG <20	3 (1.5)	19 (41.3)	46.2 (12.8, 166.5)

^a N = 200, ^bN = 46

underlying genetic component. A heritable metabolic phenotype would provide a convenient target in the choice of candidate genes that predispose to complex disease and these studies in autistic families are currently underway.

Abnormal levels of metabolites in both transmethylation and transsulfuration pathways were surprisingly prevalent among case parents (Tables 1 and 2). Both parents had significant increases in mean plasma homocysteine and SAH levels and significant decreases in the SAM/SAH ratio, total and free GSH, and the GSH/GSSG ratio. Whether the parental metabolic abnormalities are genetically-based or the result of adult dietary deficiencies and/or chronic pro-oxidant environmental exposures cannot be determined from the present data. Further, because the blood samples were taken 3–7 years after the index pregnancy, it is not possible to know whether the maternal metabolic imbalance was present during the index pregnancy and fetal development. This is a common dilemma in studies that attempt to define maternal risk factors for adverse birth outcomes. However, it is generally accepted that adult homocysteine levels and dietary patterns during the reproductive years tend to be relatively stable (Cuco et al. 2006). For example, maternal homocysteine levels measured after pregnancy were found not to differ from pre-pregnancy values (Walker et al. 1999). Glutathione levels in healthy adults plateau between 20 and 40 years of age suggesting that adult values are also relatively stable during childbearing years (Ono et al. 2001). Nonetheless, a prospective study would be required to determine whether the observed abnormal metabolic profile is present during pregnancy and whether it could provide a maternal risk factor for having a child with autism.

Accumulating evidence suggests that epigenetic alterations may be involved in the etiology of complex neuropsychiatric diseases that do not follow classic Mendelian inheritance and are influenced by gene-environment interactions (Abdolmaleky et al. 2004; Mattson 2003; Weaver et al. 2007). For example, aberrant DNA methylation in the promoter regions of CNS *reelin* (*RLN*) and *COMT* genes has been implicated in schizophrenia and bipolar disorder (Abdolmaleky et al. 2004; Abdolmaleky et al. 2005; Abdolmaleky et al. 2006). Based on indirect evidence, several reports have speculated that epigenetic mechanisms may contribute to the development or

predisposition to autism (Schanen 2006; Nakayama et al. 2006; Lopez-Rangel and Lewis 2006). Associated with the elevated homocysteine and SAH among the case parents was a significant decrease in genome-wide DNA methylation expressed as the percent 5-methylcytosine/total cytosine in DNA (Table 3). It is well established that an increase in homocysteine levels will induce the reversal of the SAH hydrolase (SAHH) reaction causing a concomitant elevation in SAH levels (James et al. 2002; Perna et al. 2003; Castro et al. 2003). In previous studies, we and others demonstrated that plasma homocysteine and SAH levels are positively associated with genome-wide DNA hypomethylation that is most likely due to product inhibition of the DNA methyltransferase by SAH (James et al. 2002; Caudill et al. 2001; Yi et al. 2000; McKeever et al. 1995). Elevated plasma homocysteine, SAH and DNA hypomethylation are common features of autoimmune disease (Richardson 2003) and as such may be contributing factors to the increased frequency of autoimmune disease in parents of autistic children. Further, dysregulation of imprinted gene expression and maternal valproic acid exposure have been associated with elevated SAH and DNA hypomethylation and both have been implicated as risk factors for autism (Ingrosso et al. 2000; Alonso-Aperte et al. 1999; Hogart et al. 2007; Ingram et al. 2000).

The finding of genome-wide DNA hypomethylation in a significant subset of autism parents with elevated SAH provides experimental data to support earlier speculation of epigenetic mechanisms that may be associated with autism. Elevated maternal homocysteine can cross the placental membrane (Guerra-Shinohara et al. 2002) and are correlated with fetal homocysteine levels (Murphy et al. 2004). Elevation in fetal homocysteine and SAH could theoretically alter fetal methylation patterns and induce inappropriate gene expression during development that could affect predisposition to autism. In a recent study, higher maternal plasma homocysteine at preconception, prior to fetal neurogenesis, was inversely associated with cognitive achievement in the offspring (Murphy et al. 2007). Also of related interest, elevated maternal homocysteine during the third trimester was recently found to be a risk factor for schizophrenia (Bleich et al. 2007). These studies raise concern that maternal homocysteine levels should be carefully monitored and controlled especially with high risk pregnancies.

The significant difference in metabolic profiles between control and case parents was an unexpected finding. Because of the differences in mean levels of SAH, SAM/SAH and GSH/GSSG ratio between case mothers and controls, odds ratios were calculated to give an indication of the association between these metabolite levels and the likelihood of being a mother of an autistic child. Among case mothers, 54% (25/46) had SAH levels >30 $\mu\text{mol/l}$ or a SAM/SAH ratio <2.5 which was associated with 7.3-fold and 10.7-fold increased risk respectively of being a mother with an autistic child. Mothers whose GSH/GSSG ratio was <20 had a 15.2-fold increase in the likelihood of being a mother of a child with autism. Among case mothers, 41% (19/46) exhibited a simultaneous decrease in both SAM/SAH and GSH/GSSG ratios resulting in a remarkable 46-fold increase in the likelihood of being a mother of an autistic child (Table 3).

Regardless of the origin, the finding that many parents of autistic children have an abnormal metabolic profile has important health implications in that an elevation in homocysteine and SAH levels and a decrease in SAM/SAH and GSH/GSSG ratios are well-established risk factors for heart disease, autoimmune disease, structural birth defects, and neurodegenerative disease (Morrison et al. 1999; De Bree et al. 2002; Lazzarini et al. 2007; Fidelus and Tsan 1987; Hobbs et al. 2005a; Hobbs et al. 2005b; Mattson and Shea 2003; Bains and Shaw 1997). Multiple studies have demonstrated that nutritional supplementation with B vitamins can lower homocysteine and SAH levels and that antioxidant supplementation can increase glutathione levels (Brattström et al. 1998; Zaidi et al. 2005; Ullegaddi et al. 2006). If future studies determine that a similar metabolic imbalance is present before and/or during an autism pregnancy, similar intervention strategies to normalize the maternal metabolic profile could prevent placental transfer and fetal exposure to abnormal metabolite levels.

A decrease in the GSH/GSSG redox ratio has been associated with several genetic polymorphisms, chronic dietary deficiencies, and pro-oxidant environmental exposures (Hayes and Strange 2000; Lyons et al. 2000; Greene 1995; Li et al. 2007). Glutathione can also be decreased by chronic psychological stress and severe anxiety (Eskioçak et al. 2005; Chakraborti et al. 2007). The two pathways of transmethylation and transsulfuration are metabolically interdependent such that chronic deficit in glutathione will feed back to inhibit SAM synthesis (Corrales et al. 1991) and create a chronic self-perpetuating cycle that progressively decreases GSH levels. The fact that both pathways were adversely affected in many parents suggests that the initiating factors were chronic in nature.

In summary, we have uncovered a significant metabolic imbalance in transmethylation and transsulfuration

pathways in many parents that is similar to the imbalance previously observed in many autistic children. Linkage studies are underway to determine whether the shared metabolic profiles have a genetic component and psychological testing is being done to determine whether the parent profile could reflect, in part, the chronic psychological stress of coping with an autistic child. Although potentially significant, the results of this study should be considered preliminary until confirmed in subsequent studies.

Acknowledgements The authors would like to express their gratitude to the participating families affected by autism in Arkansas without whom this study would not have been possible. This research was supported, in part, with funding from the National Institute of Child Health and Development (ROI HD051873) to SJJ, and by grants from the University of Arkansas for Medical Sciences Children's University Medical Group and the Arkansas Biosciences Institute (SJJ).

References

- Abdolmaleky, H. M., Cheng, K. H., Faraone, S. V., Wilcox, M., Glatt, S. J., Gao, F., et al. (2006). Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. *Human Molecular Genetics*, *15*, 3132–3145. doi:10.1093/hmg/ddl253.
- Abdolmaleky, H. M., Cheng, K. H., Russo, A., Smith, C. L., Faraone, S. V., Wilcox, M., et al. (2005). Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: A preliminary report. *American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics*, *134*, 60–66. doi:10.1002/ajmg.b.30140.
- Abdolmaleky, H. M., Smith, C. L., Faraone, S. V., Shafa, R., Stone, W., Glatt, S. J., et al. (2004). Methylomics in psychiatry: Modulation of gene-environment interactions may be through DNA methylation. *American Journal of Medical Genetics*, *127B*, 51–59. doi:10.1002/ajmg.b.20142.
- Alonso-Aperte, E., Ubeda, N., Achon, M., Perez-Miguelsanz, J., & Varela-Moreiras, G. (1999). Impaired methionine synthesis and hypomethylation in rats exposed to valproate during gestation. *Neurology*, *52*, 750–756.
- Badcock, C., & Crespi, B. (2006). Imbalanced genomic imprinting in brain development: An evolutionary basis for the aetiology of autism. *Journal of Evolutionary Biology*, *19*, 1007–1032. doi:10.1111/j.1420-9101.2006.01091.x.
- Bains, J. S., & Shaw, C. A. (1997). Neurodegenerative disorders in humans: The role of glutathione in oxidative stress-mediated neuronal death. *Brain Research. Brain Research Reviews*, *25*, 335–358. doi:10.1016/S0165-0173(97)00045-3.
- Beaudet, A. L. (2002). Is medical genetics neglecting epigenetics? *Genetics in Medicine*, *4*, 399–402. doi:10.1097/00125817-200209000-00013.
- Bleich, S., Frieling, H., & Hillemecher, T. (2007). Elevated prenatal homocysteine levels and the risk of schizophrenia. *Archives of General Psychiatry*, *64*, 980–981. doi:10.1001/archpsyc.64.8.980.
- Brattström, L., Landgren, F., Israelsson, B., Lindgren, A., Hultberg, B., Andersson, A., et al. (1998). Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. *BMJ (Clinical Research Ed)*, *316*, 894–898.

- Castro, R., Rivera, I., Struys, E. A., Jansen, E. E. W., Ravasco, P., Camilo, M. E., et al. (2003). Increased, homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. *Clinical Chemistry*, *49*, 1292–1296. doi:10.1373/49.8.1292.
- Caudill, M. A., Wang, J. C., Melnyk, S., Pogribny, I. P., Jernigan, S., Collins, M. D., et al. (2001). Intracellular S-adenosylhomocysteine concentrations predict global DNA hypomethylation in tissues of methyl deficient cystathionine β -synthase heterozygous mice. *The Journal of Nutrition*, *131*, 2811–2818.
- CDC. (2005). <http://www.medicalhomeinfo.org/health/Autism%20downloads/AutismAlarm.pdf>.
- Chakraborti, A., Gulati, K., Banerjee, B. D., & Ray, A. (2007). Possible involvement of free radicals in the differential neuro-behavioral responses to stress in male and female rats. *Behavioural Brain Research*, *179*, 321–325. doi:10.1016/j.bbr.2007.02.018.
- Chauhan, A., Chauhan, V., Brown, W. T., & Cohen, I. (2004). Oxidative stress in autism: Increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin—the antioxidant proteins. *Life Sciences*, *75*, 2539–2549. doi:10.1016/j.lfs.2004.04.038.
- Corrales, F., Ochoa, P., Rivas, C., Martin-Lomas, M., Mato, J. M., & Pajares, M. A. (1991). Inhibition of glutathione synthesis in the liver leads to S-adenosyl-L-methionine synthetase reduction. *Hepatology (Baltimore, Md.)*, *14*, 528–533.
- Cuco, G., Fernandez-Ballart, J., Sala, J., Viladrich, C., Iranzo, R., Vila, J., et al. (2006). Dietary patterns and associated lifestyles in preconception, pregnancy and postpartum. *European Journal of Clinical Nutrition*, *60*, 364–371. doi:10.1038/sj.ejcn.1602324.
- De Bree, A., Verschuren, W. M., Kromhout, D., Kluijtmans, L. A., & Blom, H. J. (2002). Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. *Pharmacological Reviews*, *54*, 599–618. doi:10.1124/pr.54.4.599.
- Dreosti, I. E. (1998). Nutrition, cancer, and aging. *Annals of the New York Academy of Sciences*, *854*, 371–377. doi:10.1111/j.1749-6632.1998.tb09917.x.
- Eskiocak, S., Gozen, A. S., Yapar, S. B., Tavas, F., Kilic, A. S., & Eskiocak, M. (2005). Glutathione and free sulphhydryl content of seminal plasma in healthy medical students during and after exam stress. *Human Reproduction (Oxford, England)*, *20*, 2595–2600. doi:10.1093/humrep/dei062.
- Feil, R. (2006a). Environmental and nutritional effects on the epigenetic regulation of genes. *Mutation Research*, *600*, 46–57. doi:10.1016/j.mrfmmm.2006.05.029.
- Fidelus, R. K., & Tsan, M. F. (1987). Glutathione and lymphocyte activation: A function of ageing and auto-immune disease. *Immunology*, *61*, 503–508.
- Filomeni, G., Rotilio, G., & Ciriolo, M. R. (2002). Cell signalling and the glutathione redox system. *Biochemical Pharmacology*, *64*, 1057–1064. doi:10.1016/S0006-2952(02)01176-0.
- Frey, B. N., Andrezza, A. C., Kunz, M., Gomes, F. A., Quevedo, J., Salvador, M., et al. (2007). Increased oxidative stress and DNA damage in bipolar disorder: A twin-case report. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, *31*, 283–285. doi:10.1016/j.pnpbp.2006.06.011.
- Friso, S., & Choi, S. W. (2002). Gene-nutrient interactions and DNA methylation. *The Journal of Nutrition*, *132*, 2382S–2387S.
- Friso, S., Choi, S. W., Dolnikowski, G. G., & Selhub, J. (2002a). A method to assess genomic DNA methylation using high-performance liquid chromatography/electrospray ionization mass spectrometry. *Analytical Chemistry*, *74*, 4526–4531. doi:10.1021/ac020050h.
- Friso, S., Choi, S. W., Girelli, D., Mason, J. B., Dolnikowski, G. G., Bagley, P. J., et al. (2002b). A common mutation in the 5, 10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. *Proceedings of the National Academy of Sciences of the United States of America*, *99*, 5606–5611. doi:10.1073/pnas.062066299.
- Fuso, A., Seminara, L., Cavallaro, R. A., D'Anselmi, F., & Scarpa, S. (2005). S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. *Molecular and Cellular Neurosciences*, *28*, 195–204. doi:10.1016/j.mcn.2004.09.007.
- Giordano, V., Peluso, G., Iannuccelli, M., Benatti, P., Nicolai, R., & Calvani, M. (2007). Systemic and brain metabolic dysfunction as a new paradigm for approaching Alzheimer's dementia. *Neurochemical Research*, *32*, 555–567. doi:10.1007/s11064-006-9125-8.
- Greene, L. S. (1995). Asthma and oxidant stress: Nutritional, environmental, and genetic risk factors. *Journal of the American College of Nutrition*, *14*, 317–324.
- Guerra-Shinohara, E. M., Paiva, A. A., Rondo, P. H., Yamasaki, K., Terzi, C. A., & D'Almeida, V. (2002). Relationship between total homocysteine and folate levels in pregnant women and their newborn babies according to maternal serum levels of vitamin B12. *BJOG*, *109*, 784–791. doi:10.1111/j.1471-0528.2002.01307.x.
- Hayes, J. D., & Strange, R. C. (2000). Glutathione S-transferase polymorphisms and their biological consequences. *Pharmacology*, *61*, 154–166. doi:10.1159/000028396.
- Hermann, A., Gowher, H., & Jeltsch, A. (2004). Biochemistry and biology of mammalian DNA methyltransferases. *Cellular and Molecular Life Sciences*, *61*, 2571–2587. doi:10.1007/s00018-004-4201-1.
- Hobbs, C. A., Cleves, M. A., Melnyk, S., Zhao, W., & James, S. J. (2005a). Congenital heart defects and abnormal maternal biomarkers of methionine and homocysteine metabolism. *The American Journal of Clinical Nutrition*, *81*, 147–153.
- Hobbs, C. A., Cleves, M. A., Zhao, W., Melnyk, S., & James, S. J. (2005b). Congenital heart defects and maternal biomarkers of oxidative stress. *The American Journal of Clinical Nutrition*, *82*, 598–604.
- Hogart, A., Nagarajan, R. P., Patzel, K. A., Yasui, D. H., & LaSalle, J. M. (2007). 15q11–13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders. *Human Molecular Genetics*, *16*, 691–703. doi:10.1093/hmg/ddm014.
- Ingrosso, D., D'angelo, S., di Carlo, E., Perna, A. F., Zappia, V., & Galletti, P. (2000). Increased methyl esterification of altered aspartyl residues in erythrocyte membrane proteins in response to oxidative stress. *European Journal of Biochemistry*, *267*, 4397–4405. doi:10.1046/j.1432-1327.2000.01485.x.
- Jacob, R. A., Gretz, D. M., Taylor, P. C., James, S. J., Pogribny, I. P., Miller, B. J., et al. (1998). Moderate folate depletion increases plasma homocysteine and decreases lymphocyte DNA methylation in postmenopausal women. *The Journal of Nutrition*, *128*, 1204–1212.
- James, S. J., Cutler, P., Melnyk, S., Jernigan, S., Janak, L., Gaylor, D. W., et al. (2004). Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. *The American Journal of Clinical Nutrition*, *80*, 1611–1617.
- James, S. J., Melnyk, S., Jernigan, S., Cleves, M. A., Halsted, C. H., Wong, D. H., et al. (2006). Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. *American Journal of Medical Genetics. Part B, Neuro-psychiatric Genetics*, *141*, 947–956. doi:10.1002/ajmg.b.30366.
- James, S. J., Melnyk, S., Pogribna, M., Pogribny, I. P., & Caudill, M. A. (2002). Elevation in S-adenosylhomocysteine and DNA hypomethylation: Potential epigenetic mechanism for homocysteine-related pathology. *The Journal of Nutrition*, *132*, 2361S–2366S.

- Kates, W. R., Burnette, C. P., Eliez, S., Strunge, L. A., Kaplan, D., Landa, R., et al. (2004). Neuroanatomic variation in monozygotic twin pairs discordant for the narrow phenotype for autism. *The American Journal of Psychiatry*, *161*, 539–546. doi:10.1176/appi.ajp.161.3.539.
- Kilbourne, A. M., Brar, J. S., Drayer, R. A., Xu, X., & Post, E. P. (2007). Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder. *Psychosomatics*, *48*, 412–417. doi:10.1176/appi.psy.48.5.412.
- Kuratomi, G., Iwamoto, K., Bundo, M., Kusumi, I., Kato, N., Iwata, N., et al. (2007). Aberrant DNA methylation associated with bipolar disorder identified from discordant monozygotic twins. *Molecular Psychiatry*, *13*(4), 429–441.
- Li, Z., Dong, T., Proschel, C., & Noble, M. (2007). Chemically diverse toxicants converge on Fyn and c-Cbl to disrupt precursor cell function. *PLoS Biology*, *5*, e35. doi:10.1371/journal.pbio.0050035.
- Lopez-Rangel, E., & Lewis, M. E. (2006). Loud and clear evidence for gene silencing by epigenetic mechanisms in autism and related neurodevelopmental disorders. *Clinical Genetics*, *69*, 21–22. doi:10.1111/j.1399-0004.2006.00543a.x.
- Lyons, J., Rauh-Pfeiffer, A., Yu, Y. M., Lu, X. M., Zurakowski, D., Tompkins, R. G., et al. (2000). Blood glutathione synthesis rates in healthy adults receiving a sulfur amino acid-free diet. *Proceedings of the National Academy of Sciences of the United States of America*, *97*, 5071–5076. doi:10.1073/pnas.090083297.
- Mattson, M. P. (2003). Methylation and acetylation in nervous system development and neurodegenerative disorders. *Ageing Research Reviews*, *2*, 329–342. doi:10.1016/S1568-1637(03)00013-8.
- Mattson, M. P., & Shea, T. B. (2003). Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. *Trends in Neurosciences*, *26*, 137–146. doi:10.1016/S0166-2236(03)00032-8.
- McKeever, M., Molloy, A., Weir, D. G., Young, P. B., Kennedy, D. G., Kennedy, S., et al. (1995). An abnormal methylation ratio induces hypomethylation in vitro in the brain of pig and man, but not in rat. *Clinical Science*, *88*, 73–79.
- Melnyk, S., Pogribna, M., Pogribny, I., Hine, R. J., & James, S. J. (1999). A new HPLC method for the simultaneous determination of oxidized and reduced plasma amino thiols using coulometric electrochemical detection. *The Journal of Nutritional Biochemistry*, *10*, 490–497. doi:10.1016/S0955-2863(99)00033-9.
- Melnyk, S., Pogribna, M., Pogribny, I. P., Yi, P., & James, S. J. (2000). Measurement of plasma and intracellular S-adenosylmethionine and S-adenosylhomocysteine utilizing coulometric electrochemical detection: Alterations with plasma homocysteine and pyridoxal 5'-phosphate concentrations. *Clinical Chemistry*, *46*, 265–272.
- Ming, X., Stein, T. P., Brimacombe, M., Johnson, W. G., Lambert, G. H., & Wagner, G. C. (2005). Increased excretion of a lipid peroxidation biomarker in autism. *Prostaglandins Leukotrienes and Essential Fatty Acids*, *73*, 379–384. doi:10.1016/j.plefa.2005.06.002.
- Morrison, J. A., Jacobsen, D. W., Sprecher, D. L., Robinson, K., Khoury, P., & Daniels, S. R. (1999). Serum glutathione in adolescent males predicts parental coronary heart disease. *Circulation*, *100*, 2244–2247.
- Murphy, M. M., Fernandez-Ballart, J. D., Arija, V., Scott, J. M., Molloy, A. M., & Canals, J. (2007). Maternal homocysteine at preconception is negatively correlated with cognitive achievement in children at 4 months and 6 years of age. Conference Proceedings, 6th International Conference on Homocysteine Metabolism. *Clinical Chemistry and Laboratory Medicine*, *45*(5), A23.
- Murphy, M. M., Scott, J. M., Arija, V., Molloy, A. M., & Fernandez-Ballart, J. D. (2004). Maternal homocysteine before conception and throughout pregnancy predicts fetal homocysteine and birth weight. *Clinical Chemistry*, *50*, 1406–1412. doi:10.1373/clinchem.2004.032904.
- Nakayama, A., Masaki, S., & Aoki, E. (2006). *Nihon Shinkei Seishin Yakurigaku Zasshi*, *26*, 209–212. (Genetics and epigenetics in autism).
- Niculescu, M. D., & Zeisel, S. H. (2002). Diet, methyl donors and DNA methylation: Interactions between dietary folate, methionine and choline. *The Journal of Nutrition*, *132*, 2333S–2335S.
- Ono, H., Sakamoto, A., & Sakura, N. (2001). Plasma total glutathione concentrations in healthy pediatric and adult subjects. *Clinica Chimica Acta*, *312*, 227–229. doi:10.1016/S0009-8981(01)00596-4.
- Pastore, A., Federici, G., Bertini, E., & Piemonte, F. (2003). Analysis of glutathione: Implication in redox and detoxification. *Clinica Chimica Acta*, *333*, 19–39. doi:10.1016/S0009-8981(03)00200-6.
- Pennington, K., Beasley, C. L., Dicker, P., Fagan, A., English, J., Pariante, C. M., et al. (2007). Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. *Molecular Psychiatry* [Epub ahead of print].
- Perna, A. F., Ingrosso, D., Lombardi, C., Acanfora, F., Satta, E., Cesare, C. M., et al. (2003). Possible mechanisms of homocysteine toxicity. *Kidney International*, *63*, S137–S140. doi:10.1046/j.1523-1755.63.s84.33.x.
- Razin, A. (1998). CpG methylation, chromatin structure and gene silencing - a three-way connection. *The EMBO Journal*, *17*, 4905–4908. doi:10.1093/emboj/17.17.4905.
- Regland, B., Johansson, B. V., & Gottfries, C.-G. (1994). Homocysteinemia and schizophrenia as a case of methylation deficiency. *Journal of Neural Transmission*, *98*, 143–152. doi:10.1007/BF01277017.
- Reik, W., & Dean, W. (2001). DNA methylation and mammalian epigenetics. *Electrophoresis*, *22*, 2838–2843. doi:10.1002/1522-2683(200108)22:14<2838::AID-ELPS2838>3.0.CO;2-M.
- Richardson, B. (2003). DNA methylation and autoimmune disease. *Clinical Immunology (Orlando, Fla.)*, *109*, 72–79. doi:10.1016/S1521-6616(03)00206-7.
- Robertson, K. D., & Jones, P. A. (2000). DNA methylation: Past, present and future directions. *Carcinogenesis*, *21*, 461–467. doi:10.1093/carcin/21.3.461.
- Samaco, R. C., Hogart, A., & LaSalle, J. M. (2005). Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3. *Human Molecular Genetics*, *14*, 483–492. doi:10.1093/hmg/ddi045.
- Schanen, N. C. (2006). Epigenetics of autism spectrum disorders. *Human Molecular Genetics*, *15*(Spec No 2), R138–R150.
- Sogut, S., Zoroglu, S. S., Ozyurt, H., Ramazan, Y. H., Ozugurlu, F., Sivasli, E., et al. (2003). Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. *Clinica Chimica Acta*, *331*, 111–117. doi:10.1016/S0009-8981(03)00119-0.
- Ullegaddi, R., Powers, H. J., & Gariballa, S. E. (2006). Antioxidant supplementation with or without B-group vitamins after acute ischemic stroke: A randomized controlled trial. *Journal of Parenteral and Enteral Nutrition*, *30*, 108–114.
- Walker, M. C., Smith, G. N., Perkins, S. L., Keely, E. J., & Garner, P. R. (1999). Changes in homocysteine levels during normal pregnancy. *American Journal of Obstetrics and Gynecology*, *180*, 660–664. doi:10.1016/S0002-9378(99)70269-3.
- Weaver, I. C., D'Alessio, A. C., Brown, S. E., Hellstrom, I. C., Dymov, S., Sharma, S., et al. (2007). The transcription factor nerve growth factor-inducible protein a mediates epigenetic programming: Altering epigenetic marks by immediate-early genes. *The Journal of Neuroscience*, *27*, 1756–1768. doi:10.1523/JNEUROSCI.4164-06.2007.

- Wu, G., Fang, Y. Z., Yang, S., Lupton, J. R., & Turner, N. D. (2004). Glutathione metabolism and its implications for health. *The Journal of Nutrition*, *134*, 489–492.
- Yao, J. K., Leonard, S., & Reddy, R. (2006a). Altered glutathione redox state in schizophrenia. *Disease Markers*, *22*, 83–93.
- Yao, Y., Walsh, W. J., McGinnis, W. R., & Pratico, D. (2006b). Altered vascular phenotype in autism: Correlation with oxidative stress. *Archives of Neurology*, *63*, 1161–1164. doi:[10.1001/archneur.63.8.1161](https://doi.org/10.1001/archneur.63.8.1161).
- Yi, P., Melnyk, S., Pogribna, M., Pogribny, I. P., Hines, R. J., & James, S. J. (2000). Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. *The Journal of Biological Chemistry*, *275*, 29318–29323. doi:[10.1074/jbc.M002725200](https://doi.org/10.1074/jbc.M002725200).
- Zaidi, S. M., Al Qirim, T. M., & Banu, N. (2005). Effects of antioxidant vitamins on glutathione depletion and lipid peroxidation induced by restraint stress in the rat liver. *Drugs in R&D*, *6*, 157–165. doi:[10.2165/00126839-200506030-00004](https://doi.org/10.2165/00126839-200506030-00004).
- Zoroglu, S. S., Armutcu, F., Ozen, S., Gurel, A., Sivasli, E., Yetkin, O., et al. (2004). Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism. *European Archives of Psychiatry and Clinical Neuroscience*, *254*, 143–147. doi:[10.1007/s00406-004-0456-7](https://doi.org/10.1007/s00406-004-0456-7).